Price$12.26-0.56 (-4.41%)
01:30 PM07:45 PM
News · 26 weeks57-8%
2025-12-142026-06-07
Mix3890d
- SEC Filings17(45%)
- Insider6(16%)
- Other6(16%)
- Leadership5(13%)
- Analyst4(11%)
Latest news
25 items- PRImmunic to Participate in Investor, Industry and Scientific Conferences in JuneNEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June:June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. Erik Lundgren, Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat at this summit taking place in New York and virtually. The pre-recorded presentation will be available for registered attendees via the H.C. Wainwright conference site starting on Monday, Jun
- INSIDERSEC Form 4 filed by Chief Executive Officer Lundgren Erik4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lundgren Erik3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECSEC Form DEF 14A filed by Immunic Inc.DEF 14A - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis –– Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood –NEW YORK, May 28, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-r
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® –– Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition Toward a Commercial-Stage Multiple Sclerosis Company –NEW YORK, May 27, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning on June 1, 2026. Mr. Lundgren succeeds Daniel Vitt, Ph.D., who will retain responsibility for scienti
- ANALYSTWolfe Research initiated coverage on ImmunicWolfe Research initiated coverage of Immunic with a rating of Outperform
- INSIDERSEC Form 3 filed by new insider Bonney Michael W3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization –– Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis –NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026. Simona Skerjanec, M.Pharm, MBA, will transition from Interim Chairperson to continue serving as a member of the Board.Mr. Bonney brings more than three d
- SECImmunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECSEC Form 10-Q filed by Immunic Inc.10-Q - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer –– Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 –– Raised $200 Million in an Oversubscribed Private Placement, with Potential for up to an Additional $200 Million –NEW YORK, May 13, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update."W
- SECSEC Form EFFECT filed by Immunic Inc.EFFECT - IMMUNIC, INC. (0001280776) (Filer)
- SECAmendment: SEC Form S-3/A filed by Immunic Inc.S-3/A - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor and Medical Conferences in MayNEW YORK, April 30, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May:May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in Prague, Czech Republic and virtually. To schedule a meeting, please use the Bio€quity Europe conference portal or contact Jessica Breu at: jessica.breu@imux.com.May 2
- INSIDERSEC Form 4 filed by Chief Medical Officer Panzara Michael A.4 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Panzara Michael A.3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies –– Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development –NEW YORK, April 28, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026. Dr. Panzara will lead the company's development organization, including clinical development, medical affairs, and reg
- SECImmunic Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Announces 1-for-10 Reverse Stock SplitNEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026.Immunic's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "IMUX" and will begin trading on a reverse stock split-adjusted basis at the opening of the Nasdaq Capital Market on April 27, 2026. The new CUSIP number for the split-adjusted common stock will be 4525EP200.At the Company's special me
- SECAmendment: SEC Form 10-K/A filed by Immunic Inc.10-K/A - IMMUNIC, INC. (0001280776) (Filer)
IMUX FAQ
7 questionsWhat does Immunic Inc. do?
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from...Where does IMUX stock trade?
Immunic Inc. (IMUX) is listed on NASDAQ.What sector and industry is IMUX in?
Immunic Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Immunic Inc. go public?
Immunic Inc. (IMUX) completed its IPO in 2014.What are analysts saying about IMUX?
Immunic Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-05-22.What companies are similar to IMUX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IMUX side-by-side with any of them on Quantisnow.How can I track IMUX on Quantisnow?
Quantisnow aggregates Immunic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMUX to receive live email and push alerts on every new disclosure.